Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,364.48 -0.25 (-0.02%)
Delayed Quote Updated: 2:30 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly ↗
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs. 
Via Investor's Business Daily
News headline image
Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
From Hims & Hers
Via Business Wire
News headline image
2 Growth Stocks to Buy in November Without Any Hesitation ↗
They have both outperformed the broader equity market over the long run. 
Via The Motley Fool
News headline image
Here's the 1 Stock I'd Most Want to Buy If the Market Crashes ↗
Investors should look to defensive stocks in the healthcare sector during a major market correction. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
OPKO Health (OPK) Q3 2026 Earnings Call Transcript ↗
Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech. 
Via The Motley Fool
Topics Earnings
News headline image
These 6 Stocks Make Up a Big Share of the S&P 500 ↗
Six tech stocks make up nearly a third of the S&P 500. Here's how AI spending is shaping each one's results. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Elanco (ELAN) reports earnings tomorrow: what to expect
Animal health company Elanco (NYSE:ELAN) will be reporting results this Friday before market hours. Here’s what to expect. Elanco beat analysts’ revenue expe... 
Via StockStory
Topics Artificial Intelligence
News headline image
The Nasdaq-100 Is Outperforming Nvidia, Microsoft, Amazon, Meta Platforms, Alphabet, and Tesla This Year. Here's My Favorite Low-Cost ETF to Buy the Dip. ↗
Many megacap growth stocks are underperforming the major indexes this year. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
If the S&P 500 Falls 20%, Here's the 1 ETF I'd Buy Hand Over Fist ↗
Some individual stocks keep falling. The broader U.S. stock market has always bounced back. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. ↗
Viking aims to enter the weight loss drug market. 
Via The Motley Fool
News headline image
What to expect from ANI Pharmaceuticals’s (ANIP) Q3 earnings
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Thursday before market open. Here’s what investors should ... 
Via StockStory
News headline image
Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu... 
Via StockStory
Topics Artificial Intelligence
News headline image
Viatris (VTRS) Q3 earnings report preview: what to look for
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what investors should know. Viatris be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Amphastar Pharmaceuticals (AMPH) to report earnings tomorrow: here is what to expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting results this Thursday after market close. Here’s what to look for. Amphastar ... 
Via StockStory
News headline image
Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Dirt Cheap Dividend Stocks to Buy in November 2026 ↗
These high-yielding stocks pay up to 7.4% in dividends. 
Via The Motley Fool
Topics Economy
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets 
From FN Media
Via GlobeNewswire
News headline image
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Retatrutide Research Draws Attention in Costa Rica as Demand for Reliable Scientific Information Grows
Via Press Release Distribution Service
News headline image
Phibro Animal Health (PAHC) reports earnings tomorrow: what to expect
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be announcing earnings results this Wednesday after market hours. Here’s what inv... 
Via StockStory
News headline image
Eli Lilly Stock: Is It Still a Buy at $1,400? ↗
The company just released some incredible quarterly results, but its valuation is also fairly high. 
Via The Motley Fool
News headline image
Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy? ↗
The drugmaker continues its impressive run. 
Via The Motley Fool
News headline image
GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge? ↗
Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to... 
Via MarketBeat
Topics ETFs
News headline image
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗
The market for GLP-1 drugs is forecast to explode. It may be understated still. 
Via The Motley Fool
News headline image
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. ↗
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. 
Via The Motley Fool
News headline image
Amneal (AMRX) Q3 earnings: what to expect
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results tomorrow before market hours. Here’s what to expect. Amneal beat analys... 
Via StockStory
News headline image
What to expect from Pfizer’s (PFE) Q3 earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven... 
Via StockStory
News headline image
Corcept (CORT) to report earnings tomorrow: here is what to expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday after market hours. Here’s what to look for. Corcept be... 
Via StockStory
Topics Artificial Intelligence
News headline image
Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts? ↗
Eli Lilly posted 39% YOY revenue growth in Q3 2026 on strong Mounjaro and Zepbound sales, raising full-year guidance even as Medicare's GLP-1 Bridge program pressures drug pricing. 
Via MarketBeat
News headline image
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? ↗
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>